Evidence map›Paper›PMID 38794892›Full record

Trial reportJapanese journal of clinical oncology2024

Elranatamab in Japanese patients with relapsed/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3.

Shinsuke Iida, Satoshi Ito, Hisayuki Yokoyama, Tadao Ishida, Yuya Nagai, Hiroshi Handa, Shigeki Ito, Yoichi Kamei, Masatoshi Nakamura, Kenshi Suzuki

2 registry-linked trialsAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Japanese journal of clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04649359 phase2active not recruitingnot on this map

Magnetismm-3 an open-label, multicenter, non-randomized phase 2 study of elranatamab (pf-06863135) monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-cd38 antibody

TypeinterventionalSponsorPfizerRan2021 to 2026Enrolled187ConditionsMultiple MyelomaArmsElranatamab (PF-06863135)
NCT04798586 phase1completednot on this map

A phase i, open label study to evaluate the safety and pharmacokinetic of pf 06863135, a b cell maturation antigen (bcma) cd3 bispecific antibody, as a single agent in japanese participants with relapsed/refractory advanced multiple myeloma

TypeinterventionalSponsorPfizerRan2021 to 2023Enrolled4ConditionsRelapsed or Refractory Multiple MyelomaArmsElranatamab (PF-06863135)
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Kawasumi Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8602, Japan.
Satoshi ItoDepartment of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Graduate School of Medicine, Yamagata, Japan.
Hisayuki YokoyamaDepartment of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Yuya NagaiDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Hiroshi HandaDepartment of Hematology, Gunma University Graduate School of Medicine, Maebashi, Japan.
Shigeki ItoDivision of Hematology & Oncology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Yahaba, Japan.
Yoichi KameiPfizer R&D Japan GK, Tokyo, Japan.
Masatoshi NakamuraPfizer R&D Japan GK, Tokyo, Japan.
Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.

Funding

Pfizer
6 · The paper itself

Abstract

backgroundDespite advances, most patients with multiple myeloma (MM) experience relapse and repeat multiple treatment lines, highlighting an unmet need for patients with relapsed or refractory MM (RRMM). Bispecific antibodies are a new option, but their efficacy and safety in Japanese patients are unknown.

methodsThis was an analysis of Japanese patients receiving elranatamab monotherapy in MagnetisMM-2 (NCT04798586) and MagnetisMM-3 (NCT04649359). Both studies evaluated a priming dose regimen of elranatamab followed by weekly subcutaneous doses, in patients with disease progression while receiving or who were intolerant to ≥3 prior therapies (≥1 proteasome inhibitor, ≥1 immunomodulatory drug and ≥1 anti-CD38 monoclonal antibody). The primary endpoints were dose limiting toxicities (DLTs) in MagnetisMM-2 and confirmed objective response rate (ORR) in MagnetisMM-3. In both, key secondary endpoints included safety, tolerability, duration of response, time to response, progression-free survival and overall survival.

resultsIn MagnetisMM-2 (N = 4) and MagnetisMM-3 (n = 12), median ages were 68.5 and 66.5 years, respectively. No DLTs were observed in MagnetisMM-2. ORRs were 50.0% (95% CI, 6.8-93.2) and 58.3% (95% CI, 27.7-84.8) in MagnetisMM-2 and MagnetisMM-3, respectively. All patients experienced treatment-emergent adverse events in MagnetisMM-2 (grade 3/4: 75.0%) and MagnetisMM-3 (grade 3/4: 100%); cytokine release syndrome occurred in 100% (grade 3/4: 25.0%) and 58.3% (no grade 3/4) of patients, respectively. Neither study reported immune effector cell-associated neurotoxicity syndrome.

conclusionsNo new safety signals were observed, and ORRs were similar to that of the overall MagnetisMM-3 trial population, supporting further studies of elranatamab in Japanese patients with RRMM. ClinicalTrials.gov identifier: NCT04798586 (MagnetisMM-2), NCT04649359 (MagnetisMM-3).

Indexed as

Multiple MyelomaAgedAged, 80 and overAntibodies, BispecificAntibodies, Monoclonal, HumanizedDrug Resistance, NeoplasmEast Asian PeopleFemaleHumansJapanMaleMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalAntibodies, BispecificAntibodies, Monoclonal, HumanizedB-cell maturation antigenbispecific antibodiesJapanese patientsmultiple myelomatriple-class refractory

Identifiers

PMID38794892
PMCPMC11374885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.